TTC9C

Across TCGA pan-cancer cohorts, TTC9C RNA differs between tumor and matched normal tissue in 14 of 18 cancer types tested, making tumor–normal expression one of TTC9C’s most consistent transcriptional readouts.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where TTC9C RNA is more highly expressed in tumor relative to normal tissue. In most cancer types TTC9C is over-expressed in tumor, although a few such as KICH show the opposite, repressed pattern.

BLCA, KIRC, and HNSC are the cancer types where TTC9C tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TTC9C RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BLCA	All	III,IV	+0.944	<.001	12	view →
KIRC	Male	IV	+0.778	<.001	12	view →
HNSC	Male	III,IV	+0.944	<.001	11	view →
LIHC	Female	II,III,IV	+1.060	<.001	9	view →
LUAD	Male	II,III,IV	+0.665	<.001	9	view →
COAD	Male	II,III,IV	+0.639	<.001	9	view →
STAD	Female	All	+0.968	<.001	8	view →
BRCA	All	III,IV	+0.615	<.001	6	view →
LUSC	Male	II,III,IV	+0.529	<.001	6	view →
CHOL	All	All	+1.955	<.001	5	view →
KIRP	All	II,III,IV	+0.481	.009	4	view →
KICH	Female	All	−0.590	.001	3	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 14 lineages.

TTC9C–BLCA

Open the BLCA breakdown →